New antibody drug aims to halt skin and hair loss

NCT ID NCT07554222

Recruiting now Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called IBI3013, which blocks a protein (IL-15) involved in immune attacks. It includes 160 people: healthy volunteers first, then people with active vitiligo or severe alopecia areata. The main goal is to check safety and how the drug moves through the body, not yet whether it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI3013 (an antibody that blocks IL-15, a protein involved in immune attacks)
What this could lead to: If it works, this could point toward a new treatment for vitiligo and alopecia areata by calming the immune system.
What could go wrong: This is a very early Phase 1 trial focused on safety and dosing, not on effectiveness. It may not work or could have side effects. Results are years away.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE NON-SEGMENTAL VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACTIVE NON-SEGMENTAL VITILIGO HEALTHY SEVERE ALOPECIA AREATA

Contacts and locations

Locations

Huashan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.